Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Fruquintinib/Sintilimab Generates Favorable PFS Outcomes in Advanced RCC

March 19th 2025

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

March 14th 2025

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Dr McGregor on the Rationale of Analyzing the Efficacy and Safety Exposure Response of Tivozanib in RCC

March 13th 2025

Bradley McGregor, MD, discusses the rationale for analyzing efficacy and safety exposure response to tivozanib in patients with renal cell carcinoma.

Casdatifan Monotherapy Shows Early Efficacy Signals and Tolerable Safety Profile in Pretreated ccRCC

March 12th 2025

Treatment with casdatifan was well tolerated and showed meaningful clinical activity in patients with previously treated ccRCC.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

Cemiplimab Plus Chemotherapy Yields Responses in Advanced/Metastatic Penile Carcinoma

March 11th 2025

Cemiplimab-based therapy is effective and has a safety profile consistent with prior reports in locally advanced/metastatic penile cancer.

Latent Viruses in Human Genome Inspire Novel Directions for Kidney Cancer Immunotherapy

March 10th 2025

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.

Dr Barragan-Carrillo on Global Disparities in Clinical Trial Availability in RCC

March 5th 2025

Regina Barragan-Carrillo, MD, discusses findings from an analysis of global RCC clinical trial availability in high- vs low-to-middle–income countries.

Tivozanib Preserves QOL From Baseline to Week 24 in ICI-Pretreated RCC

March 4th 2025

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

Disparities in RCC Trial Access Illuminate the Need for Global Scientific Collaboration

March 3rd 2025

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Addition of CBM588 to Cabozantinib/Nivolumab Shows Potential in Metastatic RCC

March 3rd 2025

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.

Dr Beckermann on the Role of Tivozanib in Advanced Clear Cell RCC

February 28th 2025

Kathryn E. Beckermann, MD, PhD, details the role of tivozanib as second- and third-line therapy in patients with locally advanced or metastatic ccRCC.

Dr Ebrahimi on Clinical Outcomes With the Addition of CBM588 to Cabozantinib and Nivolumab in RCC

February 27th 2025

Hedyeh Ebrahimi, MD, MPH, discusses clinical outcomes with CBM588 plus cabozantinib and nivolumab in metastatic renal cell carcinoma.

Clinical Trials, Randomized Data Are Key to Further Refine Treatment Selection in Advanced Non–Clear Cell RCC

February 27th 2025

Charles B. Nguyen, MD, provides insight into current challenges faced in the non–clear cell RCC landscape beyond the NCCN’s recent guideline updates.

Neoadjuvant MVAC/Pembrolizumab Generates Unprecedented pCR Rates in Non-Urothelial MIBC: With Chandler Park, MD; Petros Grivas, MD, PhD; and Ruben Raychaudhuri, MD

February 26th 2025

Drs Park, Grivas, and Raychaudhuri discuss a trial of neoadjuvant aMVAC plus pembrolizumab in patients with non-urothelial muscle-invasive bladder cancer.

Updated Clinical Trial Data Reflect Efforts to Optimize IO Combos in Non-ccRCC and MIBC, Fine-Tune ADT-Based Regimens in Prostate Cancer

February 25th 2025

Pedro Barata, MD, provides insights on key updates in RCC, MIBC, and prostate cancer, as discussed during a State of the Science Summit™.

Durvalumab Plus Chemo May be Promising Neoadjuvant Option in UTUC

February 25th 2025

A phase 3 study will be initiated after completion of the first neoadjuvant phase 2 trial of platinum-based chemotherapy plus immunotherapy in UTUC.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium

February 19th 2025

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.